08:04 AM EDT, 08/18/2025 (MT Newswires) -- Soligenix ( SNGX ) said Monday that the US Food and Drug Administration has granted orphan drug designation to dusquetide for the treatment of Behcet's disease, an inflammatory disorder of the blood vessels.

The decision was made after a review of the recent phase 2a clinical results showing biological efficacy and safety in patients with Behcet's disease, the company said.